REPLIGEN CORP Restructuring and Related Cost, Cost Incurred to Date
REPLIGEN CORP (RGEN) had Restructuring and Related Cost, Cost Incurred to Date of $83.30 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Restructuring and Related Activities
us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 · last filed 2026-02-26
- 2025-12-31: Restructuring and Related Cost, Cost Incurred to Date $83.30M.
- 2025-09-30: Restructuring and Related Cost, Cost Incurred to Date $83.30M.
- 2025-06-30: Restructuring and Related Cost, Cost Incurred to Date $83.30M.
- 2025-03-31: Restructuring and Related Cost, Cost Incurred to Date $81.10M.
| Period end | Restructuring and Related Cost, Cost Incurred to Date |
|---|---|
| 2025-12-31 | $83.30M 10-K · filed 2026-02-26 |
| 2025-09-30 | $83.30M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $83.30M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $81.10M 10-Q · filed 2025-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |